Skip to content

An Exploratory Investigation of a Supplement to Enhance Sleep Quality and Quantity

An Exploratory Investigation of a Supplement to Enhance Sleep Quality and Quantity

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05521243
Enrollment
64
Registered
2022-08-30
Start date
2022-05-09
Completion date
2022-09-30
Last updated
2022-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sleep, Sleep Disturbance, Sleep Hygiene

Keywords

Sleep, Sleep Disturbance, Sleep Quality, Sleep Quantity

Brief summary

This double-blind study will examine the effectiveness of Dream Powder and Dream Powder Extra Strength over a six week period. The main outcomes of interest will be sleep quantity and quality, as well as self-reported changes in sleep across the study period.

Interventions

DIETARY_SUPPLEMENTBeam Organics Dream Powder

The Dream Powder and Dream Powder Extra Strength both use nano hemp, reishi, magnesium. L-theanine, and melatonin to promote a healthy sleep pattern

DIETARY_SUPPLEMENTBeam Organics Dream Powder Extra Strength

The Dream Powder and Dream Powder Extra Strength both use nano hemp, reishi, magnesium. L-theanine, and melatonin to promote a healthy sleep pattern

DIETARY_SUPPLEMENTPlacebo

The main ingredients in the placebo are: Coconut milk powder, cocoa, cinnamon, monk fruit, natural vanilla flavor

Sponsors

Citruslabs
CollaboratorINDUSTRY
Beam
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
24 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* Self-reported issues with sleep Must be in good overall health with no unstable medical conditions Must own a wearable sleep tracker (i.e., Apple Watch, FitBit, Whoop, etc.) Must be willing to discontinue any supplements meant to assist with sleep.

Exclusion criteria

* Females who are pregnant or breastfeeding Diagnosis of insomnia or sleep apnea Taking a prescription medication that affects sleep Anyone with a pre-existing condition that would prevent them from adhering to the protocol Anyone with a known history of past severe allergic reactions

Design outcomes

Primary

MeasureTime frameDescription
Perceived Changes in Sleep Quality as reported by questionnaires6 WeeksExamined across the six week trial with questionnaires. These questionnaires will occur at Baseline, Week 2, Week 4, and Week 6, and will gather information about their ability to fall asleep, stay asleep, and the overall amount of sleep they get on average during the past week.
Perceived Changes in Sleep Quantity as reported by questionnaires6 weeksExamined across the six week trial with questionnaires. These questionnaires will occur at Baseline, Week 2, Week 4, and Week 6, and will gather information about their ability to fall asleep, stay asleep, and the overall amount of sleep they get on average during the past week.
Perceived Changes in Sleep Habits as reported by Questionnaires6 weeksExamined across the six week trial with questionnaires. These questionnaires will occur at Baseline, Week 2, Week 4, and Week 6, and will gather information about their ability to fall asleep, stay asleep, and the overall amount of sleep they get on average during the past week.
Participant Perceptions of Sleep6 weeksExamined across the six week trial with questionnaires. These questionnaires will occur at Baseline, Week 2, Week 4, and Week 6, and will gather information about their ability to fall asleep, stay asleep, and the overall amount of sleep they get on average during the past week.

Secondary

MeasureTime frameDescription
Examine changes in device measured sleep across the six week trial.6 WeeksSleep will be measured with fitness trackers to provide an objective outcome measure of sleep across the six week trial. Both sleep time and sleep quality will be examined. Participants will report their sleep data from the previous week at Baseline, Week 2, Week 4, and Week 6.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026